AZTR AMEX
Azitra, Inc.
1W: -21.4%
1M: -27.1%
3M: -11.3%
YTD: -52.7%
1Y: -81.7%
3Y: -100.0%
$0.13
+0.00 (+2.72%)
Weekly Expected Move ±14.0%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (32)
Zacks Research Has Bullish Estimate for Azitra Q3 Earnings
Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short Interest
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
Azitra GAAP EPS of -$0.17
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
AZTR: More Background on Cosmetic Opportunity
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Azitra secures U.S. patent for ATR-12 skin disease treatment program
Why Are Shares Of Azitra Rising?
12 Health Care Stocks Moving In Friday's Intraday Session
Dow Falls Over 100 Points; FedEx Posts Upbeat Earnings
12 Health Care Stocks Moving In Friday's Pre-Market Session
Azitra CEO-backed private placement priced up to $10.5M, potential $20.9M; stock jumps 90%
Why Planet Labs Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending
12 Health Care Stocks Moving In Monday's After-Market Session
Azitra receives notice of non-compliance with NYSE American Listing standards
FY2026 Earnings Estimate for Azitra Issued By Zacks Research
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
AZTR: New Site for ATR-04 Trial
AZTR: New Site for ATR-04 Trial
Azitra GAAP EPS of -$2.25 beats by $0.23
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s Why
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules